A prospective study of dietary selenium intake and risk of type 2 diabetes
© Stranges et al; licensee BioMed Central Ltd. 2010
Received: 21 May 2010
Accepted: 21 September 2010
Published: 21 September 2010
Growing evidence raises concern about possible associations of high selenium exposure with diabetes in selenium-replete populations such as the US. In countries with lower selenium status, such as Italy, there is little epidemiological evidence on the association between selenium and diabetes. This study examined the prospective association between dietary selenium intake and risk of type 2 diabetes.
The ORDET cohort study comprised a large sample of women from Northern Italy (n = 7,182). Incident type 2 diabetes was defined as a self-report of a physician diagnosis, use of antidiabetic medication, or a hospitalization discharge. Dietary selenium intake was measured by a semi-quantitative food-frequency questionnaire at the baseline examination (1987-1992). Participants were divided in quintiles based on their baseline dietary selenium intake.
Average selenium intake at baseline was 55.7 μg/day. After a median follow-up of 16 years, 253 women developed diabetes. In multivariate logistic regression analyses, the odds ratio for diabetes comparing the highest to the lowest quintile of selenium intake was 2.39, (95% CI: 1.32, 4.32; P for linear trend = 0.005). The odds ratio for diabetes associated with a 10 μg/d increase in selenium intake was 1.29 (95% CI: 1.10, 1.52).
In this population, increased dietary selenium intake was associated with an increased risk of type 2 diabetes. These findings raise additional concerns about the association of selenium intake above the Recommended Dietary Allowance (55 μg/day) with diabetes risk.
Selenium is a key component of a number of selenoproteins involved in essential enzymatic functions, such as redox homeostasis, thyroid hormone metabolism, immunity and reproduction . Because of antioxidant properties of selenoproteins, and because selenate mimics insulin activity in experimental models [2, 3], selenium was expected to prevent type 2 diabetes and cardiovascular disease (CVD) . However, recent findings from observational studies and randomised clinical trials have raised concerns with respect to possible adverse cardio-metabolic effects of high selenium exposure, at least in well-nourished populations. Specifically, several unrelated studies from the US indicate that high selenium status or selenium supplementation is associated with an increased diabetes risk [5–8]. Furthermore, recent evidence from several populations indicates that high selenium exposure may also be associated with an adverse lipid profile [9–12] and hypertension , raising additional concerns about metabolic toxicity of high selenium exposure and prolonged use of selenium supplements .
Dietary intake of selenium varies considerably between countries and regions largely due to the variability of the selenium content of soil and hence of plant foods and animal forage . Current recommendations on selenium intake are based on optimizing the activity of plasma glutathione peroxidases, which are maximized at intakes as high as 55 μg/day . In the US, selenium intake ranges from 60-220 μg/day [8, 12, 13, 15] and it is unclear if there are health benefits of increased selenium intake above the Recommended Dietary Allowance (RDA), or if metabolic toxicity might occur at these levels. Selenium intakes in Europe are lower than in the US, but with large between-country variability ranging from adequate or marginally adequate (Western and Central Europe: 30-90 μg/day) to low or deficient intake (Eastern European countries: 7-30 μg/day) .
There is little epidemiological evidence on the association of selenium with diabetes among European populations [17, 18]. The objective of the present study was thus to examine the association of dietary selenium intake with risk of incident type 2 diabetes in the ORDET cohort study, a large sample of women from Northern Italy .
The ORDET study (HORmones and Diet in the ETiology of Breast Cancer) is an ongoing prospective follow-up study of 10,786 women residents of Varese province in Northern Italy . Between June 1987 and June 1992, healthy women 34 to 70 years of age were asked to join the study by coming to the recruitment center. Participants were recruited at public meetings, through radio, television and newspaper advertising, and at breast cancer prevention/early diagnosis units. Women with a history of cancer, bilateral ovariectomy, or liver disease, and women receiving hormone therapy in the three months prior to recruitment to the study were not eligible for the study. We excluded women who did not fill in the lifestyle questionnaire (N = 96), who reported the presence of type 2 diabetes at the baseline assessment (N = 203), who did not compile the food frequency questionnaire because it was not available at the beginning of the study (N = 1,552), or who had missing data in anthropometric variables (N = 54). We further excluded participants in whom the ratio of total energy intake (determined from the food frequency questionnaire) to basal metabolic rate was at either extreme of the distribution (cut-offs 0.5 and 99.5 percentiles) (N = 73), to reduce the impact of implausible extreme values , as well as women who died during follow-up from causes other than type 2 diabetes (N = 336). Finally, 1,290 women could not be re-contacted over the follow-up and were further excluded. After all these exclusions, the final cohort comprised 7,182 participants. All participants signed an informed consent form. The Ethical Review Board of the Italian National Cancer Institute of Milan approved the study.
Diet was assessed using a semi-quantitative food-frequency questionnaire designed to capture local dietary habits . Frequency of consumption and average daily consumption of food and beverage items over the previous year were estimated using a 107-item questionnaire. To estimate daily consumption of macronutrients and daily energy intake, these items were linked to the Italian Food Tables for epidemiological studies .
We used two sources of data to estimate the selenium content of the food items included in the ORDET food frequency questionnaire. For several food items, we used the nutritional database maintained by the Italian National Institute of Nutrition, which in its 1997 edition reported the average selenium content of several foodstuffs distributed in Italy . Since the selenium composition of some items in the ORDET questionnaire (particularly for cereals and meats) could not be retrieved in this database nor were they available from other national sources, we carried out a specific measurement by selecting samples of these foods distributed in Northern Italy from 1996 through 1998 and determining their average selenium content by hydride-generation atomic absorption spectrometry .
A lifestyle questionnaire was also completed by each participant to collect detailed information on reproductive history, alcohol consumption, smoking habits, medical history, occupation, education and other socioeconomic variables. Weight and height were measured at enrolment by trained nurses according to a standardized protocol. Body mass index (BMI) was calculated as weight divided by height squared (kg/m2).
Case ascertainment and verification
Follow-up information was collected through a telephone interview in 2006-2007. The follow-up questionnaire included update information on weight, menopausal status, incident disease and other factors. Follow-up was available for approximately 79.1% of the baseline cohort (mean follow-up: 16 years). The telephone follow-up interviews asked whether participants had received a diagnosis of type 2 diabetes from a physician after the baseline examination or if they were taking medications for treatment of diabetes. In addition to the follow-up questionnaire, information on hospitalizations and medication use during follow-up was obtained by linking regional hospital discharge databases, and prescription drug databases to the ORDET database mainly via social security numbers.
In the present study, incident type 2 diabetes was defined by the presence of at least three of the following conditions: 1) a self-report of a physician diagnosis in the follow-up questionnaire; 2) a self-report of use of insulin or oral hypoglycemic medication in the follow-up questionnaire; 3) evidence of a prescription for insulin or oral hypoglycemic medication by linkage with regional prescription drug database; or 4) a hospital discharge record with the diagnosis of diabetes by linkage with medical discharge records. These criteria complied with the protocol of the InterAct Study, an EU-funded large scale collaboration involving nine European Countries and 500,000 subjects with over 10,000 incident diabetic cases http://www.inter-act.eu/.
The study population was categorized in quintiles of energy-adjusted selenium intake at baseline using the residual method . Odds ratios (OR) for developing type 2 diabetes comparing the highest to the lowest quintile of selenium intake were estimated by logistic regression analysis. We used two levels of adjustment: model 1 (reduced model) was adjusted for age, education and menopausal status; model 2 (fully-adjusted model) was further adjusted for BMI (as a linear term), smoking (never, past, current), alcohol intake (abstainers, ≤ 12 g/day, > 12 g/day), energy intake (not from alcohol), saturated/polyunsaturated fat ratio, animal proteins, total carbohydrates, and body weight change (delta-weight) between the baseline and follow-up examinations. Tests for trend across selenium intake quintiles were derived from likelihood ratio tests comparing models with and without a variable including the median selenium intake at each quintile as a continuous variable. We tested the interaction of selenium intake with BMI categories (BMI ≤ 25 & > 25) and with menopausal status using a likelihood ratio test that compared the model that included the product term and the model that did not include it. We used STATA software (version 10.0; Stata Corp., TX) for statistical analysis.
Baseline characteristics* of participants according to diabetes status at the follow-up examination in the ORDET Study (N = 7,182)
Current smoker (%)
Education (%) > 8 years
Post-menopausal status (%)
Total proteins (g/day)
Animal proteins (g/day)
Ratio saturated/polyunsaturated fatty acids
Total carbohydrates (g/day)
Selenium intake (μg/day)
Food sources of selenium in the ORDET Study
Leafy vegetable raw
Baseline characteristics* of participants according to energy-adjusted quintiles† of dietary selenium intake in the ORDET Study (N = 7,182)
Quintiles of dietary selenium intake (μg/day)
Average Se intake (μg/d)
Current smoker (%)
Education (%) > 8 years
Post-menopausal status (%)
Total proteins (g/day)
Animal proteins (g/day)
Ratio saturated/polyunsaturated fatty acids
Total carbohydrates (g/day)
Odds Ratios (95% Confidence Intervals) of incident type 2 diabetes by quintiles* of dietary selenium intake in the ORDET Study
Quintiles of dietary selenium intake (μg/day)
N° cases of diabetes
Range Se intake (μg/day)
Model 1 (reduced)
Model 2 (fully-adjusted)
When selenium was used as a continuous variable, the odds ratios associated with a 10 μg/d increase in selenium intake were 1.29 (95% CI: 1.17, 1.41) in the reduced model, and 1.29 (95% CI: 1.10, 1.52) in the fully adjusted model. The linearity of the relationship between selenium intake and risk of diabetes was confirmed in spline regression models (not shown). There was no statistical evidence that BMI, menopausal status, smoking and alcohol intake modified the association of selenium intake with diabetes risk (data not shown).
In this prospective study, dietary selenium intake showed a strong and graded association with the risk of type 2 diabetes in a large sample of Italian women. The association was independent of a number of potential confounding factors including socio-demographic, anthropometric, lifestyle and dietary variables. To our knowledge, this is one of the few epidemiological studies to examine the prospective relationship of dietary selenium intake with incident type 2 diabetes in Europe.
Recent findings from observational studies and randomised clinical trials from the US, a selenium-replete population, indicate that high selenium status or selenium supplementation may be associated with an increased risk of type 2 diabetes [5–8]. Data from the Third National Health and Nutrition Examination Survey (NHANES III)  and from NHANES 2003-2004  showed significant cross-sectional associations between high serum selenium levels and the prevalence of type 2 diabetes in representative samples of the US population. Furthermore, selenium supplementation (200 μg/d) in the Nutritional Prevention of Cancer (NPC) trial, conducted in the Eastern US, was associated with an increased risk of incident type 2 diabetes compared to placebo (hazard ratio, 1.55, 95% CI: 1.03, 2.33). The increase in risk was largely limited to participants with high baseline selenium levels (hazard ratio of 2.70 in the highest tertile of serum selenium) . Finally, the Selenium and Vitamin E Cancer Prevention Trial (SELECT), conducted among 35,000 North American men aged 50 and older, was prematurely stopped because of lack of efficacy of vitamin E and selenium supplementation (200 μg/d) in cancer prevention and because of a small, though not statistically significant increase in the number of cases of adult onset diabetes in participants taking only selenium (relative risk compared to placebo 1.07, 99% CI: 0.94, 1.22) . In disagreement with these studies, cross-sectional findings from the Health Professionals Follow-up Study showed lower toenail selenium levels among diabetic men (with or without cardiovascular disease) than among healthy control participants . In addition, a longitudinal analysis of US young adults participating in the CARDIA Study showed a lower risk of type 2 diabetes in the highest quintile of toenail selenium compared to the lowest (hazard ratio 0.59, 95% CI: 0.36, 0.97), although the point estimates in the intermediate quintiles were null .
With regard to European populations, there is little epidemiological evidence. In the Supplementation with Antioxidant Vitamins and Minerals (SU.VI.MAX) trial, an antioxidant supplement containing 100 μg of selenium, 120 mg of vitamin C, 30 mg of vitamin E, 6 mg of β-carotene, and 20 mg of zinc had no effect on plasma glucose levels after 7.5 years of follow-up, but in this study there was a significant positive association between plasma selenium and glucose levels at both baseline and follow-up . Conversely, a recent report from the EVA (Epidemiology of Vascular Ageing) study in France showed that higher plasma selenium concentrations (1.19-1.97 μmol/L) were associated with a marginally significant decreased risk of dysglycemia (impaired fasting glucose or diabetes) in men over a 9-year follow-up . No association was found in women. It should be noted that in an earlier analysis of the same study, plasma selenium concentrations were positively, though non-significantly, associated with baseline glucose levels in women and with prevalent diabetes in men .
Mechanistic evidence that may explain an association between high selenium exposure and increased risk of type 2 diabetes is limited; therefore any such discussion is highly speculative at the present time. Selenium has a narrow therapeutic range and large inter-individual variability in terms of metabolic sensitivity [27, 28]. Selenium species such as selenite and selenate may impair insulin responsiveness in rats and induce a catabolic response in muscle with glycogen depletion and increased rates of glycolysis . Moreover, high-selenium diets may stimulate the release of glucagon, promoting hyperglycemia , or may induce over-expression of glutathione peroxidase-1 (GPx-1) and other antioxidant selenoproteins resulting in insulin resistance and obesity [31–33]. Likewise in humans, a strongly positive correlation between GPx activity and insulin resistance was found in a group of non-diabetic pregnant women . From a mechanistic point of view, selenium intakes above the level recommended for optimal activity of antioxidant selenoproteins such as glutathione peroxidases (55 μg/day, resulting in serum or plasma concentrations of 70-90 μg/L) [16, 35], will result in the non-specific incorporation of selenomethionine replacing methionine in albumin and other proteins . The metabolic pathways involving this extra pool of selenium are not fully understood, and may be responsible for some of the adverse effects of high selenium exposure on glucose metabolism.
The present study may suffer from the inherent limitations associated with the use of self-reported semi-quantitative food-frequency questionnaires, an approach prone to misclassification of the exposure of interest. Indeed, the correlation between dietary selenium intake and selenium biomarkers has been inconsistent across studies, ranging from positive, strong associations [36, 37] to weak or null associations [38, 39]. A clear limitation of our study is the lack of validation data for food-frequency estimates of selenium intake in our population, which makes it impossible for us to correct selenium and other nutritional covariates for random or systematic measurement error. However, while the use of questionnaire data to estimate selenium intake has raised concerns in settings with high variability in the selenium content of foods and high frequency of use of vitamin and mineral supplements, several factors point to the validity of the selenium intake estimates in the present study. First, the ORDET study compiled a detailed database of the selenium content of local foods, with ad hoc measurements of the selenium content of a variety of foods. Second, previous studies have shown little variability of selenium in food contents as well as of selenium status throughout Italy , making it easier to estimate selenium intake through questionnaire data. Indeed, the range of dietary selenium intake in the present study is compatible with previous estimates of selenium status, based on biomarkers, from Italian populations [40–42]. Finally, despite the lack of data on the use of dietary supplements containing selenium in the ORDET study, a nationwide survey conducted in Italy in the 90s  showed a small percentage of supplement users among women (less than 5%). Thus, it is likely that very few participants were using supplements during the 80s when the ORDET sample was recruited. In our setting, assessing selenium exposure through evaluation of dietary intake may even have advantages over selenium biomarkers, which may be influenced by the intake of other nutrients such as methionine , by smoking and other life-style variables , drug use , and the chemical species of selenium itself .
As a further potential limitation of the present study, we cannot rule out confounding effects by unmeasured (e.g. family history of diabetes, physical activity) or unknown factors that may have contributed to our findings. The association between selenium intake and diabetes could be driven by a common dietary factor or by general over-nutrition. For example, red meat, the main source of selenium in our study, has been positively associated with type 2 diabetes in prospective settings among women , and contains compounds such as preservatives, additives, and nitrates that might confound the observed associations of selenium intake with diabetes risk.
Our study may have underestimated the incidence of type 2 diabetes, as case identification was based on self-report and record linkage to hospital and prescription databases. It should be noted, however, that case ascertainment of incident diabetes in the follow up of the ORDET study complied with the protocol of the InterAct Study, an EU-funded large scale collaboration involving 350,000 subjects with over 10,000 incident diabetic cases http://www.inter-act.eu/. In addition, given the voluntary nature of the study population, we cannot rule out the potential for a "healthy volunteer' bias, which may have contributed to a low incidence of type 2 diabetes in this study.
Finally, given the prospective design, differential misclassification seems unlikely and non-differential misclassification would result in an underestimation of the association between selenium intake and diabetes risk . Major strengths of the present study are its prospective nature, which limits the possibility of reverse causality, high standardization of data collection, length and high rate of follow-up.
The use of selenium enriched foods, fertilizers, and supplements has increased markedly in many Western countries in recent years [47, 48] because of the perception that selenium can potentially reduce the risk of cancer and other chronic diseases. Hence, from a public health perspective it is essential to ensure that selenium fortification of the food supply and use of selenium supplements do not exacerbate the current diabetes epidemic.
The present study adds to the evidence of an association between high selenium exposure and potential diabetes risk. Future studies are needed to investigate the link between selenium exposure and metabolic effects in more detail across different ranges of exposure, as well as potential underlying mechanisms [14, 49].
- Burk RF: Selenium, an antioxidant nutrient. Nutr Clin Care. 2002, 5: 75-79. 10.1046/j.1523-5408.2002.00006.x.View ArticlePubMedGoogle Scholar
- Mueller AS, Pallauf J: Compendium of the antidiabetic effects of supranutritional selenate doses. In vivo and in vitro investigations with type II diabetic db/db mice. J Nutr Biochem. 2006, 17: 548-560. 10.1016/j.jnutbio.2005.10.006.View ArticlePubMedGoogle Scholar
- Stapleton SR: Selenium: an insulin-mimetic. Cell Mol Life Sci. 2000, 57: 1874-1879. 10.1007/PL00000669.View ArticlePubMedGoogle Scholar
- Stranges S, Marshall JR, Trevisan M, Natarajan R, Donahue RP, Combs GF, Farinaro E, Clark LC, Reid ME: Effects of selenium supplementation on cardiovascular disease incidence and mortality: secondary analyses in a randomized clinical trial. Am J Epidemiol. 2006, 163: 694-699. 10.1093/aje/kwj097.View ArticlePubMedGoogle Scholar
- Bleys J, Navas-Acien A, Guallar E: Serum selenium and diabetes in U.S. Adults. Diabetes Care. 2007, 30: 829-834. 10.2337/dc06-1726.View ArticlePubMedGoogle Scholar
- Stranges S, Marshall JR, Natarajan R, Donahue RP, Trevisan M, Combs GF, Cappuccio FP, Ceriello A, Reid ME: Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Ann Intern Med. 2007, 147: 217-223.View ArticlePubMedGoogle Scholar
- Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL, Baker LH, Coltman CA: Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009, 301: 39-51. 10.1001/jama.2008.864.View ArticlePubMedGoogle Scholar
- Laclaustra M, Navas-Acien A, Stranges S, Ordovas JM, Guallar E: Serum selenium concentrations and diabetes in US adults: National Health and Nutrition Examination Survey (NHANES) 2003-2004. Environ Health Perspect. 2009, 117: 1409-1413.View ArticlePubMedPubMed CentralGoogle Scholar
- Hercberg S, Bertrais S, Czernichow S, Noisette N, Galan P, Jaouen A, Tichet J, Briancon S, Favier A, Mennen L, Roussel AM: Alterations of the lipid profile after 7.5 years of low-dose antioxidant supplementation in the SU.VI.MAX Study. Lipids. 2005, 40: 335-342. 10.1007/s11745-006-1391-3.View ArticlePubMedGoogle Scholar
- Bleys J, Navas-Acien A, Stranges S, Menke A, Miller ER, Guallar E: Serum selenium and serum lipids in US adults. Am J Clin Nutr. 2008, 88: 416-423.PubMedPubMed CentralGoogle Scholar
- Stranges S, Laclaustra M, Ji C, Cappuccio FP, Navas-Acien A, Ordovas JM, Rayman M, Guallar E: Higher selenium status is associated with adverse blood lipid profile in British adults. J Nutr. 2010, 140: 81-87. 10.3945/jn.109.111252.View ArticlePubMedPubMed CentralGoogle Scholar
- Laclaustra M, Stranges S, Navas-Acien A, Ordovas JM, Guallar E: Serum selenium and plasma lipids in US adults: National Health and Nutrition Examination Survey (NHANES) 2003-2004. Atherosclerosis. 2010, 210: 643-8. 10.1016/j.atherosclerosis.2010.01.005.View ArticlePubMedPubMed CentralGoogle Scholar
- Laclaustra M, Navas-Acien A, Stranges S, Ordovas JM, Guallar E: Serum selenium levels and hypertension in the US population. Circ Cardiovasc Qual Outcomes. 2009, 2: 369-376. 10.1161/CIRCOUTCOMES.108.831552.View ArticlePubMedPubMed CentralGoogle Scholar
- Vinceti M, Maraldi T, Bergomi M, Malagoli C: Risk of chronic low-dose selenium overexposure in humans: insights from epidemiology and biochemistry. Rev Environ Health. 2009, 24: 231-248.View ArticlePubMedGoogle Scholar
- Rayman MP: Food-chain selenium and human health: emphasis on intake. Br J Nutr. 2008, 100: 254-268.PubMedGoogle Scholar
- Food and Nutrition Board, Institute of Medicine: Dietary reference intakes for vitamin C, vitamin E, selenium, and carotenoids. A report of the Panel on Dietary Antioxidants and Related Compounds, Subcommittees on Upper Reference Levels of Nutrients and Interpretation and Uses of Dietary Reference Intakes, and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. 2000, Washington, DC: National Academy PressGoogle Scholar
- Czernichow S, Couthouis A, Bertrais S, Vergnaud AC, Dauchet L, Galan P, Hercberg S: Antioxidant supplementation does not affect fasting plasma glucose in the Supplementation with Antioxidant Vitamins and Minerals (SU.VI.MAX) study in France: association with dietary intake and plasma concentrations. Am J Clin Nutr. 2006, 84: 395-399.PubMedGoogle Scholar
- Akbaraly TN, Arnaud J, Rayman MP, Hininger-Favier I, Roussel AM, Berr C, Fontbonne A: Plasma selenium and risk of dysglycemia in an elderly French population: Results from the prospective Epidemiology of Vascular Ageing Study. Nutr Metab. 2010, 7 (21):Google Scholar
- Sieri S, Pala V, Brighenti F, Pellegrini N, Muti P, Micheli A, Evangelista A, Grioni S, Contiero P, Berrino F, Krogh V: Dietary glycemic index, glycemic load, and the risk of breast cancer in an Italian prospective cohort study. Am J Clin Nutr. 2007, 86: 1160-1166.PubMedGoogle Scholar
- Willett W, Howe GR, Kushi LH: Adjustment for total energy intake in epidemiologic studies. Am J Clin Nutr. 1997, 65: 1220S-1228S.PubMedGoogle Scholar
- Salvini S, Parpinel M, Gnagnarella P, Maisonneuve P, Turrini A: Italian food composition database for epidemiologic studies. Milan, Italy: European Institute of Oncology. 1998Google Scholar
- Carnovale E, Marletta L: Tabelle di Composizione degli Alimenti. Rome, Italy: Istituto Nazionale della Nutrizione. 1997, 1-120.Google Scholar
- Lloyd B, Holt P, Delves HT: Determination of selenium in biological samples by hydride generation and atomic absorption spectroscopy. Analyst. 1982, 107: 927-933. 10.1039/an9820700927.View ArticlePubMedGoogle Scholar
- Rajpathak S, Rimm E, Morris JS, Hu F: Toenail selenium and cardiovascular disease in men with diabetes. J Am Coll Nutr. 2005, 24: 250-256.View ArticlePubMedGoogle Scholar
- He K, Liu K, Morris SJ, Daviglus ML, Colangelo L, Jacobs DR, Loria CM: Longitudinal association of toenail selenium levels with incidence of type 2 diabetes: 18-year follow-up of the CARDIA trace element study. Circulation. 2009, 119: e300-Google Scholar
- Coudray C, Roussel AM, Mainard F, Arnaud J, Favier A: Lipid peroxidation level and antioxidant micronutrient status in a pre-aging population; correlation with chronic disease prevalence in a French epidemiological study. J Am Coll Nutr. 1997, 16: 584-591.PubMedGoogle Scholar
- Whanger P, Vendeland S, Park YC, Xia Y: Metabolism of sub-toxic levels of selenium in animals and humans. Ann Clin Lab Sci. 1996, 26: 99-113.PubMedGoogle Scholar
- Vinceti M, Wei ET, Malagoli C, Bergomi M, Vivoli G: Adverse health effects of selenium in humans. Rev Environ Health. 2001, 16: 233-251.View ArticlePubMedGoogle Scholar
- Fürnsinn C, Englisch R, Ebner K, Nowotny P, Vogl C, Waldhäusl W: Insulin-like vs. non-insulin-like stimulation of glucose metabolism by vanadium, tungsten, and selenium compounds in rat muscle. Life Sci. 1996, 59: 1989-2000. 10.1016/S0024-3205(96)00550-4.View ArticlePubMedGoogle Scholar
- Satyanarayana S, Sekhar JR, Kumar KE, Shannika LB, Rajanna B, Rajanna S: Influence of selenium (antioxidant) on gliclazide induced hypoglycaemia/anti hyperglycaemia in normal/alloxan-induced diabetic rats. Mol Cell Biochem. 2006, 283: 123-7. 10.1007/s11010-006-2387-2.View ArticlePubMedGoogle Scholar
- McClung JP, Roneker CA, Mu W, Lisk DJ, Langlais P, Liu F, Lei XG: Development of insulin resistance and obesity in mice overexpressing cellular glutathione peroxidase. Proc Natl Acad Sci USA. 2004, 101: 8852-7. 10.1073/pnas.0308096101.View ArticlePubMedPubMed CentralGoogle Scholar
- Li X, Chen H, Epstein PN: Metallothionein and catalase sensitize to diabetes in nonobese diabetic mice: reactive oxygen species may have a protective role in pancreatic beta-cells. Diabetes. 2006, 55: 1592-604. 10.2337/db05-1357.View ArticlePubMedGoogle Scholar
- Wang XD, Vatamaniuk MZ, Wang SK, Roneker CA, Simmons RA, Lei XG: Molecular mechanisms for hyperinsulinaemia induced by overproduction of selenium-dependent glutathione peroxidase-1 in mice. Diabetologia. 2008, 51: 1515-24. 10.1007/s00125-008-1055-3.View ArticlePubMedGoogle Scholar
- Chen X, Scholl TO, Leskiw MJ, Donaldson MR, Stein TP: Association of glutathione peroxidase activity with insulin resistance and dietary fat intake during normal pregnancy. J Clin Endocrinol Metab. 2003, 88: 5963-8. 10.1210/jc.2003-030544.View ArticlePubMedGoogle Scholar
- Burk RF, Norsworthy BK, Hill KE, Motley AK, Byrne DW: Effects of chemical form of selenium on plasma biomarkers in a high-dose human supplementation trial. Cancer Epidemiol Biomarkers Prev. 2006, 15: 804-810. 10.1158/1055-9965.EPI-05-0950.View ArticlePubMedGoogle Scholar
- Duffield AJ, Thomson CD: A comparison of methods of assessment of dietary selenium intakes in Otago, New Zealand. Br J Nutr. 1999, 82: 131-138.View ArticlePubMedGoogle Scholar
- González S, Huerta JM, Fernández S, Patterson EM, Lasheras C: Food intake and serum selenium concentration in elderly people. Ann Nutr Metab. 2006, 50: 126-131. 10.1159/000090633.View ArticlePubMedGoogle Scholar
- Hunter DJ, Morris JS, Chute CG, Kushner E, Colditz GA, Stampfer MJ, Speizer FE, Willett WC: Predictors of selenium concentration in human toenails. Am J Epidemiol. 1990, 132: 114-122.PubMedGoogle Scholar
- Satia JA, King IB, Morris JS, Stratton K, White E: Toenail and plasma levels as biomarkers of selenium exposure. Ann Epidemiol. 2006, 16: 53-58. 10.1016/j.annepidem.2005.02.011.View ArticlePubMedGoogle Scholar
- Morisi G, Patriarca M, Marano G, Giampaoli S, Taggi F: Age and sex specific reference serum selenium levels estimated for the Italian population. Ann Ist Super Sanita. 1989, 25: 393-404.PubMedGoogle Scholar
- Jossa F, Trevisan M, Krogh V, Farinaro E, Giumetti D, Fusco G, Galasso R, Panico S, Frascatore S, Mellone C, Mancini M: Serum selenium and coronary heart disease risk factors in southern Italian men. Atherosclerosis. 1991, 87: 129-134. 10.1016/0021-9150(91)90015-U.View ArticlePubMedGoogle Scholar
- Sesana G, Baj A, Toffoletto F, Sega R, Ghezzi L: Plasma selenium levels of the general population of an area in northern Italy. Sci Total Environ. 1992, 120: 97-102. 10.1016/0048-9697(92)90220-M.View ArticlePubMedGoogle Scholar
- Turrini A, Saba A, Perrone D, Cialfa E, D'Amicis A: Food consumption patterns in Italy: the INN-CA Study 1994-1996. Eur J Clin Nutr. 2001, 55: 571-588. 10.1038/sj.ejcn.1601185.View ArticlePubMedGoogle Scholar
- Lloyd B, Lloyd RS, Clayton BE: Effect of smoking, alcohol and other factors on the selenium status of a healthy population. J Epidemiol Community Health. 1983, 37: 213-217. 10.1136/jech.37.3.213.View ArticlePubMedPubMed CentralGoogle Scholar
- Song Y, Manson JE, Buring JE, Liu S: A prospective study of red meat consumption and type 2 diabetes in middle-aged and elderly women: the women's health study. Diabetes Care. 2004, 27: 2108-15. 10.2337/diacare.27.9.2108.View ArticlePubMedGoogle Scholar
- Copeland KT, Checkoway H, McMichael AJ, Holbrook RH: Bias due to misclassification in the estimation of relative risk. Am J Epidemiol. 1977, 105: 488-495.PubMedGoogle Scholar
- Millen AE, Dodd KW, Subar AF: Use of vitamin, mineral, nonvitamin, and nonmineral supplements in the United States: The 1987, 1992, and 2000 National Health Interview Survey results. J Am Diet Assoc. 2004, 104: 942-950. 10.1016/j.jada.2004.03.022.View ArticlePubMedGoogle Scholar
- Broadley MR, White PJ, Bryson RJ, Meacham MC, Bowen HC, Johnson SE, Hawkesford MJ, McGrath SP, Zhao FJ, Breward N, Harriman M, Tucker M: Biofortification of UK food crops with selenium. Proc Nutr Soc. 2006, 65: 169-181. 10.1079/PNS2006490.View ArticlePubMedGoogle Scholar
- Mueller AS, Mueller K, Wolf NM, Pallauf J: Selenium and diabetes: an enigma?. Free Radic Res. 2009, 43: 1029-59. 10.1080/10715760903196925.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2458/10/564/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.